Change to Either a Nonandrogenic or Androgenic Progestin-Containing Oral Contraceptive Preparation is Associated with Improved Sexual Function in Women with Oral Contraceptive-Associated Sexual Dysfunction

Journal of Sexual Medicine

Volumn 10, Issue 12, 2013, Pages 3069-3079

  Davis, Susan R ^a   Bitzer, Johannes ^b   Giraldi, Annamaria ^c   Palacios, Santiago ^d   Parke, Susanne ^e   Serrani, Marco ^e   Mellinger, Uwe ^e   Nappi, Rossella E ^f  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

^c Rigshospitalet   (Denmark)

^d Institute Palacios   (Spain)

^e BAYER PHARMA AG   (Germany)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

Dienogest; Estradiol Valerate; Ethinyl Estradiol; Female Sexual Dysfunction; Oral Contraception

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ABDOMINAL DISTENSION; ACUTE APPENDICITIS; ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISTRESS SYNDROME; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEMALE SEXUAL DYSFUNCTION; FEMALE SEXUAL FUNCTION INDEX; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORGASM; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL AROUSAL; SEXUAL FUNCTION; SEXUAL HEALTH; SEXUAL SATISFACTION; VAGINAL LUBRICATION; WITHDRAWAL BLEEDING;

DIENOGEST; ESTRADIOL VALERATE; ETHINYL ESTRADIOL; FEMALE SEXUAL DYSFUNCTION; ORAL CONTRACEPTION;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; MIDDLE AGED; NANDROLONE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; YOUNG ADULT;

EID: 84889089086     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12310     Document Type: Article

References (42)

1. Wallwiener CW, Wallwiener LM, Seeger H, Muck AO, Bitzer J, Wallwiener M. Prevalence of sexual dysfunction and impact of contraception in female German medical students. J Sex Med 2010;7:2139-2148.
2. Bitzer J, Tschudin S, Meier-Burgoa J, Armbruster U, Schwendke A. Effects on the quality of life of a new oral contraceptive containing 30mcg EE and 3mg drospirenone (Yasmin). Praxis 2003;92:1177-1184.
3. Higgins JA, Hoffman S, Graham CA, Sanders SA. Relationships between condoms, hormonal methods, and sexual pleasure and satisfaction: An exploratory analysis from the Women's Well-Being and Sexuality Study. Sex Health 2008;5:321-330.
4. Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 2001;64:51-58.
5. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390-398.
6. Panzer C, Wise S, Fantini G, Kang D, Munarriz R, Guay A, Goldstein I. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: A retrospective study in women with sexual dysfunction. J Sex Med 2006;3:104-113.
7. Bancroft J, Hammond G, Graham C. Do oral contraceptives produce irreversible effects on women's sexuality? J Sex Med 2006;3:567. author reply 568-70.
8. Warnock JK, Clayton A, Croft H, Segraves R, Biggs FC. Comparison of androgens in women with hypoactive sexual desire disorder: Those on combined oral contraceptives (COCs) vs. those not on COCs. J Sex Med 2006;3:878-882.
9. Graham CA, Bancroft J, Doll HA, Greco T, Tanner A. Does oral contraceptive-induced reduction in free testosterone adversely affect the sexuality or mood of women? Psychoneuroendocrinology 2007;32:246-255.
10. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91-96.
11. Strufaldi R, Pompei LM, Steiner ML, Cunha EP, Ferreira JA, Peixoto S, Fernandes CE. Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. Contraception 2010;82:147-154.
12. Greco T, Graham CA, Bancroft J, Tanner A, Doll HA. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: A comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 2007;76:8-17.
13. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas 2003;46(1 suppl):S7-16.
14. Shepherd JE. Therapeutic options in female sexual dysfunction. J Am Pharm Assoc (Wash) 2002;42:479-487. quiz 87-8.
15. Berman JR. Physiology of female sexual function and dysfunction. Int J Impot Res 2005;17(1 suppl ):S44-51.
16. Guay A, Davis SR. Testosterone insufficiency in women: Fact or fiction? World J Urol 2002;20:106-110.
17. Caruso S, Agnello C, Intelisano G, Farina M, Di Mari L, Cianci A. Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene. Contraception 2004;69:237-240.
18. Goldstein A. Medical history, physical examination, and laboratory tests for the evaluation of dyspareunia. In: Goldstein AT, Pukall CF, Goldstein I, eds. Female sexual pain disorders: Evaluation and management. Chichester, UK: Wiley-Blackwell; 2009:15.
19. Sarajari S, Wickman DS, Marin CM, Berman JR. Pilot study assessing the impact of hormonal contraceptives on serum testosterone levels and sexual function in pre-menopausal women. Fertil Steril 2004;82(2 suppl):S78-79.
20. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003;63:463-492.
21. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191-208.
22. Berner MM, Kriston L, Zahradnik H, Harter M, Rohde A. Überprüfung der Gültigkeit und Zuverlässigkeit des deutschen Female Sexual Function Index (FSFI-d). Geburtshilfe Frauenheilkd 2004;64:293-303.
23. Blumel J, Binfa L, Cataldo P, Carrasco A, Izaguirre H, Sarra S. Indice de funcion sexual femenina: Un test para evaluar la sexualidad de la mujer. Rev Chil Obstet Ginecol 2004;69:118-125.
24. Nappi RE, Albani F, Vaccaro P, Gardella B, Salonia A, Chiovato L, Spinillo A, Polatti F. Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecol Endocrinol 2008;24:214-219.
25. Peeyananjarassri K, Liabsuetrakul T, Soonthornpun K, Choobun T, Manopsilp P. Sexual functioning in postmenopausal women not taking hormone therapy in the Gynecological and Menopause Clinic, Songklanagarind Hospital measured by Female Sexual Function Index questionnaire. J Med Assoc Thai 2008;91:625-632.
26. Kerdarunsuksri A, Manusirivithaya S. Attitudes and sexual function in Thai pregnant women. J Med Assoc Thai 2010;93:265-271.
27. Carrard C, Chevret-Measson M, Lunel A, Raudrant D. Sexuality after sigmoid vaginoplasty in patients with Mayer-Rokitansky-Kuster-Hauser syndrome. Fertil Steril 2012;97:691-696.
28. Rouanne M, Massard C, Hollebecque A, Rousseau V, Varga A, Gazzah A, Neuzillet Y, Lebret T, Soria JC. Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: A prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer 2013;49:431-438.
29. Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 2008;5:357-364.
30. Davila GW, Singh A, Karapanagiotou I, Woodhouse S, Huber K, Zimberg S, Seiler J, Kopka SL. Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol 2003;188:382-388.
31. Dupuy H. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing; 1984:170-183.
32. The Psychological General Well-Being Index (PGWBI) User Manual. Lyon, France: MAPI Research Institute; 2004. Available at: http://178.23.156.107:8085/Instruments_files/USERS/pgwbi.pdf (accessed January 2013).
33. Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005;31:1-20.
34. Garcia-Becerra R, Cooney AJ, Borja-Cacho E, Lemus AE, Perez-Palacios G, Larrea F. Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins. J Steroid Biochem Mol Biol 2004;91:21-27.
35. Schneider HP. Androgens and antiandrogens. Ann N Y Acad Sci 2003;997:292-306.
36. Katsuki Y, Sasagawa S, Takano Y, Shibutani Y, Aoki D, Udagawa Y, Nozawa S. Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid. Drugs Exp Clin Res 1997;23:45-62.
37. Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, Kuhl H. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003;67:25-32.
38. Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: An open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D 2011;11:159-170.
39. Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: A randomized, open-label, single-centre study. Clin Drug Investig 2011;31:573-584.
40. Davison SL, Bell RJ, LaChina M, Holden SL, Davis SR. The relationship between self-reported sexual satisfaction and general well-being in women. J Sex Med 2009;6:2690-2697.
41. Clayton AH, Maserejian NN, Connor MK, Huang L, Heiman JR, Rosen RC. Depression in premenopausal women with HSDD: Baseline findings from the HSDD Registry for Women. Psychosom Med 2012;74:305-311.
42. Biddle AK, West SL, D'Aloisio AA, Wheeler SB, Borisov NN, Thorp J. Hypoactive sexual desire disorder in postmenopausal women: Quality of life and health burden. Value Health 2009;12:763-772.